NO20061561L - Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering - Google Patents

Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering

Info

Publication number
NO20061561L
NO20061561L NO20061561A NO20061561A NO20061561L NO 20061561 L NO20061561 L NO 20061561L NO 20061561 A NO20061561 A NO 20061561A NO 20061561 A NO20061561 A NO 20061561A NO 20061561 L NO20061561 L NO 20061561L
Authority
NO
Norway
Prior art keywords
dihydroergotamine
aerosol formulations
delivery
via pulmonary
systemic circulation
Prior art date
Application number
NO20061561A
Other languages
English (en)
Norwegian (no)
Inventor
Richard M Pavkov
Original Assignee
Map Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Pharmaceuticals Inc filed Critical Map Pharmaceuticals Inc
Publication of NO20061561L publication Critical patent/NO20061561L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20061561A 2003-09-10 2006-04-06 Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering NO20061561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50193803P 2003-09-10 2003-09-10
PCT/US2004/029632 WO2005025506A2 (fr) 2003-09-10 2004-09-10 Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire

Publications (1)

Publication Number Publication Date
NO20061561L true NO20061561L (no) 2006-06-09

Family

ID=34312325

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061561A NO20061561L (no) 2003-09-10 2006-04-06 Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering

Country Status (7)

Country Link
US (2) US20080118442A1 (fr)
EP (1) EP1663159A4 (fr)
JP (2) JP2007505136A (fr)
AU (2) AU2004272077A1 (fr)
CA (1) CA2538237A1 (fr)
NO (1) NO20061561L (fr)
WO (1) WO2005025506A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663159A4 (fr) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
CA2559915C (fr) * 2004-03-23 2013-07-02 Novartis Ag Compositions pharmaceutiques
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
PL2425820T3 (pl) * 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
WO2009047935A1 (fr) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. Particules fines
EP2252275B1 (fr) * 2008-02-13 2017-11-29 Board of Regents, The University of Texas System Flocons ouverts divisés de particules anisotropes pour une administration aux poumons améliorée
NZ590256A (en) * 2008-07-11 2013-03-28 Map Pharmaceuticals Inc INHALER CANISTER WITH PRIMELESS VALVE AND VOLUME LESS THAN 10mL
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
EP2793580A4 (fr) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc Nouveaux dérivés d'iso-ergoline
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP2935280A4 (fr) 2012-12-21 2016-05-25 Map Pharmaceuticals Inc Composés 8'-hydroxy-dihydroergotamine et compositions associées
WO2014100359A1 (fr) * 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Nouveaux dérivés d'ergoline et leurs utilisations
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2014186754A2 (fr) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Vaccins contenant un adjuvant d'aluminium solide sec et procédés associés
EP3049059B1 (fr) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Formulation intranasale à base de dhe pour le traitement des maux de tête
AU2015214146B2 (en) 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
EP3341059B1 (fr) 2015-09-10 2022-03-02 Impel NeuroPharma Inc. Dispositif d'administration nasale en ligne
CN122562777A (zh) 2015-12-02 2026-08-14 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3064274A1 (fr) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Derives d'ergoline destines a etre utilises en medecine
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
BR112020013744A8 (pt) * 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
US10532049B1 (en) 2018-08-27 2020-01-14 Pharmaceutical Industries Limited Parenteral unit dosage form of dihydroergotamine
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
CA3122396A1 (fr) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, dispositifs et procedes de traitement ou de prevention des maux de tete
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
WO2021133744A1 (fr) * 2019-12-23 2021-07-01 Scienture, Inc. Formulations de mésylate de dihydroergotamine et injecteurs pré-remplis pour l'administration thérapeutique de celles-ci
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
CA3236150A1 (fr) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Nouveaux agents therapeutiques antiviraux pan-respiratoires a petites molecules ciblant l'hote
US20230248724A1 (en) * 2021-10-29 2023-08-10 Sun Pharmaceutical Industries Limited Method of Injecting Dihydroergotamine Into The Body
EP4433040A4 (fr) 2022-01-03 2025-11-12 Lilac Therapeutics Inc Promedicaments thiol acycliques
WO2023129577A1 (fr) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Promédicaments à base de thiol cyclique
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
EP4687888A2 (fr) 2023-05-16 2026-02-11 Lilac Therapeutics, Inc. Promédicaments de phénol
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (fr) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
BE887518A (fr) * 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
US4311863A (en) * 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
EP0069715B1 (fr) * 1981-07-08 1986-11-05 Aktiebolaget Draco Inhalateur de poudre
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
FI70493C (fi) * 1982-08-19 1986-09-19 Stroemberg Oy Ab Vaexelriktare skyddad med avseende pao stighastigheten av stroem och spaenning
JPS6037556A (ja) * 1983-08-10 1985-02-26 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US4514574A (en) * 1984-01-09 1985-04-30 The Dow Chemical Company Process for separating isomeric mixtures
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US4737384A (en) * 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
ES2053549T3 (es) * 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
ES2043640T3 (es) * 1987-12-21 1994-01-01 Union Carbide Corp Fluidos supercriticos como diluyentes en la aplicacion por rociada liquida de revestimientos.
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE3905726A1 (de) * 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
JPH05501505A (ja) * 1989-04-28 1993-03-25 ライカー　ラボラトリーズ，インコーポレイティド 乾燥粉末吸入装置
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5106659A (en) * 1989-10-04 1992-04-21 Nordson Corporation Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5186164A (en) * 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
US5182040A (en) * 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
DE4117751A1 (de) * 1991-05-30 1992-12-03 Bayer Ag Verfahren zur isolierung von polycarbonaten
US6503482B1 (en) * 1991-06-10 2003-01-07 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
JP3026841B2 (ja) * 1991-12-12 2000-03-27 グラクソ、グループ、リミテッド 医 薬
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
US5196575A (en) * 1992-02-19 1993-03-23 Hoechst Celanese Corp. Supercritical separation of isomers of functional organic compounds at moderate conditions
US5314682A (en) * 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JP3750872B2 (ja) * 1993-07-14 2006-03-01 株式会社小松製作所 車両用エンジンの過給装置およびその制御方法
NZ276277A (en) * 1993-11-08 1998-04-27 Gillette Co Antiperspirant compound, in aerogel form, being an aluminium salt, a zirconium salt or an aluminium-zirconium salt
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
MX9504934A (es) * 1994-12-12 1997-01-31 Morton Int Inc Revestimientos en polvo de pelicula delgada lisa.
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6200293B1 (en) * 1997-08-27 2001-03-13 Science Incorporated Fluid delivery device with temperature controlled energy source
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
NZ509328A (en) * 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
CA2328614C (fr) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices d'administration de medicaments et procedes de fabrication et d'utilisation de ces dernieres
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
JP2003514660A (ja) * 1999-09-13 2003-04-22 シェフィールド ファーマスゥーティカルズ インコーポレイテッド エアロゾル気流制御システムおよび方法
US6346323B1 (en) * 1999-10-07 2002-02-12 Sig Pack Systems Ag Multi-layer synthetic film
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Administration d'esters medicamenteux par inhalation
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) * 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
US6560907B1 (en) * 2002-01-18 2003-05-13 Thomas Vieweg Cartridge magazine system
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
EP1663159A4 (fr) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
WO2006039631A2 (fr) * 2004-09-30 2006-04-13 Centocor, Inc. Methodes et compositions de pathologies associees au carcinome cellulaire renale
WO2008076287A2 (fr) * 2006-12-13 2008-06-26 Tuel Stephen M Procédés destinés à fabriquer des composants pharmaceutiques pour des produits médicamenteux personnalisés
PL2425820T3 (pl) * 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych

Also Published As

Publication number Publication date
JP2007505136A (ja) 2007-03-08
AU2004272077A1 (en) 2005-03-24
EP1663159A4 (fr) 2010-06-09
CA2538237A1 (fr) 2005-03-24
JP2012116841A (ja) 2012-06-21
AU2010201070A1 (en) 2010-04-15
WO2005025506A2 (fr) 2005-03-24
WO2005025506A3 (fr) 2006-03-16
US20070253913A1 (en) 2007-11-01
US20080118442A1 (en) 2008-05-22
EP1663159A2 (fr) 2006-06-07

Similar Documents

Publication Publication Date Title
WO2005025506A3 (fr) Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
US10398673B2 (en) Mast cell stabilizers treatment for systemic disorders
Vaughn et al. Single dose and multiple dose studies of itraconazole nanoparticles
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
WO2005025535A3 (fr) Procedes de preparation de compositions pharmaceutiques
WO2009095681A3 (fr) Formulations pour suspensions
WO2005025540A3 (fr) Compositions pharmaceutiques
CN115427076B (zh) 用于治疗冠状病毒感染的人去泛素化酶抑制剂
CN102740912A (zh) 一种用于产生细小的浓缩气溶胶的方法和设备
RU2005135332A (ru) Назальные фармацевтические композиции и способы их применения
WO2005048985A3 (fr) Compositions d'alpha 1-antitrypsine et procedes de traitement mettant en oeuvre de telles compositions
MX2020011474A (es) Nuevo tratamiento de enfermedades pulmonares intersticiales.
NO20051956L (no) Salmeterol superfin formulering
CN115515587A (zh) 用于治疗冠状病毒感染的6’-甲氧基辛可宁-9-醇类
WO2012116280A2 (fr) Formulations utiles pour vaccins préparés par séchage par atomisation
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
Lewis et al. New actuators versus old: reasons and results for actuator modifications for HFA solution MDIs
NO20053090L (no) Pulverformulering for innhalering inneholdende tiotropium.
Yang et al. Excipient-free, spray-dried powders for pulmonary aztreonam delivery
JPH09227373A (ja) 抗インフルエンザウイルス剤
CN111971034A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
Xu et al. A novel pullulan excipient for inhalable spray-dried powders
Steckel et al. Metered-dose inhaler add-on devices: an in vitro evaluation of the BronchoAir inhaler and several spacer devices
NO20034873L (no) Aerosolformuleringer inneholdende estere av 3,17-dihydroksy degree stratrienderivater for pulmonar avlevering
Williams III et al. Enhanced delivery of drug compositions to treat life threatening infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application